Jul 19, 2023 7:00 am EDT Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
Jul 17, 2023 7:00 am EDT Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year
Jul 7, 2023 7:00 am EDT Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer
Jun 30, 2023 7:00 am EDT Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
Jun 20, 2023 7:00 am EDT Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 12, 2023 7:00 am EDT Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging
Jun 5, 2023 7:00 am EDT Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology
Jun 3, 2023 7:00 am EDT Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
May 31, 2023 7:00 am EDT IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
